Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the stocks under $50 to buy now. On January 20, TheFly reported that H.C. Wainwright lifted the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $120 from $110 and maintained a Buy rating. The new target suggests an upside potential of 177%.
This positive outlook comes right after Soleno Therapeutics, Inc. announced its preliminary 4Q25 and full-year 2025 financial results for its VYKAT XR offering, in which the company’s preliminary unaudited full-year 2025 net revenue surpassed the firm’s estimates by $16.5 million to $18.5 million. That said, preliminary fourth-quarter 2025 net revenue is anticipated to be between $90 and $92 million. This is substantially higher than the analyst’s guidance of $73.8 million.
Copyright: zneb076 / 123RF Stock Photo
On the same day, Derek Archila from Wells Fargo also increased the price target on Soleno Therapeutics, Inc. to $114 from $106 and reaffirmed an Overweight rating, according to TheFly. While highlighting the fourth-quarter Vykat extended-release revenues beat, the firm believes FY26 forecasts are reasonable and notes that the shares are trading at a significant discount considering its free cash flow profile.
Soleno Therapeutics, Inc. is a California-based clinical-stage biopharmaceutical company specializing in novel therapeutics to treat serious illnesses. Founded in 1999, the company provides Diazoxide Choline Extended-Release tablets.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
